Yuqing Huo Selected Research

Purinergic P1 Receptors (Adenosine Receptor)

3/2024	Blockade of endothelial adenosine receptor 2A suppresses atherosclerosis in vivo through inhibiting CREB-ALK5-mediated endothelial to mesenchymal transition.
3/2024	Inactivation of adenosine receptor 2A suppresses endothelial-to-mesenchymal transition and inhibits subretinal fibrosis in mice.
1/2021	Adenosine kinase is critical for neointima formation after vascular injury by inducing aberrant DNA hypermethylation.
1/2017	Adenosine receptors and caffeine in retinopathy of prematurity.
1/2017	Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis.
5/2010	Adenosine receptor A2A deficiency in leukocytes increases arterial neointima formation in apolipoprotein E-deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuqing Huo Research Topics

Disease

25	Inflammation (Inflammations) 05/2024 - 08/2007
16	Atherosclerosis 04/2024 - 09/2002
12	Hypoxia (Hypoxemia) 10/2023 - 12/2015
12	Insulin Resistance 01/2022 - 02/2010
8	Neointima 11/2023 - 09/2002
7	Obesity 09/2019 - 12/2012
6	Non-alcoholic Fatty Liver Disease 09/2019 - 01/2012
5	Abdominal Aortic Aneurysm 05/2024 - 12/2017
5	Fibrosis (Cirrhosis) 03/2024 - 01/2019
5	Ischemia 11/2023 - 02/2006
5	Pathologic Neovascularization 11/2022 - 01/2017
5	Body Weight (Weight, Body) 01/2022 - 07/2009
4	Vascular Remodeling 04/2024 - 09/2010
4	Wounds and Injuries (Trauma) 11/2023 - 09/2010
4	Vascular Diseases (Vascular Disease) 01/2023 - 03/2009
4	Neoplasms (Cancer) 01/2023 - 04/2016
3	Pulmonary Hypertension 04/2024 - 10/2019
3	Atherosclerotic Plaque (Atheroma) 03/2024 - 06/2008
3	Thrombosis (Thrombus) 11/2023 - 01/2004
3	Heart Failure 10/2021 - 01/2019
3	Hyperglycemia 11/2017 - 07/2010
3	Retinopathy of Prematurity (Retrolental Fibroplasia) 01/2017 - 12/2015
3	Hyperoxia 01/2017 - 12/2015
2	Pulmonary Arterial Hypertension 04/2024 - 01/2023
2	Choroidal Neovascularization 03/2024 - 11/2022
2	Infarction (Infarctions) 01/2023 - 02/2006
2	Brain Injuries (Brain Injury) 01/2022 - 01/2019
2	Weight Loss (Weight Reduction) 09/2019 - 01/2019
2	Bites and Stings (Sting) 12/2018 - 01/2017
2	Blindness (Hysterical Blindness) 01/2017 - 01/2017
2	Metabolic Diseases (Metabolic Disease) 01/2017 - 06/2015
2	Liver Diseases (Liver Disease) 11/2016 - 06/2015
2	Cognitive Dysfunction 11/2016 - 01/2014
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2024
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2024
1	Macular Degeneration (Age-Related Maculopathy) 03/2024
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2023

Drug/Important Bio-Agent (IBA)

12	Adenosine (Adenocard)FDA LinkGeneric 11/2023 - 01/2017
10	Adenosine KinaseIBA 05/2024 - 11/2016
10	Apolipoproteins E (ApoE)IBA 04/2024 - 10/2004
10	EnzymesIBA 01/2023 - 06/2012
7	Proteins (Proteins, Gene)FDA Link 04/2024 - 12/2018
7	ApolipoproteinsIBA 12/2018 - 01/2003
6	Purinergic P1 Receptors (Adenosine Receptor)IBA 03/2024 - 05/2010
6	Phosphotransferases (Kinase)IBA 11/2022 - 02/2013
5	CytokinesIBA 01/2022 - 01/2004
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2014
5	Retinaldehyde (Retinal)IBA 01/2018 - 12/2015
5	P-SelectinIBA 08/2007 - 09/2002
4	CholesterolIBA 03/2024 - 07/2009
4	CollagenIBA 01/2023 - 01/2019
4	LipidsIBA 12/2022 - 12/2012
4	FructoseIBA 01/2021 - 01/2019
4	Oxygen (Dioxygen)IBA 01/2020 - 12/2015
4	Phosphofructokinase-2 (Phosphofructokinase 2)IBA 04/2016 - 02/2010
3	ABT 702IBA 05/2024 - 01/2019
3	RNA (Ribonucleic Acid)IBA 04/2024 - 01/2023
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2024 - 01/2017
3	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 10/2014
3	Messenger RNA (mRNA)IBA 01/2023 - 03/2016
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2019
3	Interleukin-6 (Interleukin 6)IBA 01/2023 - 09/2019
3	Platelet-Derived Growth FactorIBA 01/2023 - 01/2019
3	LipopolysaccharidesIBA 01/2021 - 05/2010
3	MicroRNAs (MicroRNA)IBA 01/2020 - 03/2009
3	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019 - 12/2017
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2019 - 07/2009
3	Metformin (Glucophage)FDA LinkGeneric 01/2017 - 01/2014
2	ElastinIBA 05/2024 - 11/2023
2	InflammasomesIBA 04/2024 - 01/2019
2	NAD (NADH)IBA 04/2024 - 12/2020
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2024 - 12/2020
2	istradefyllineIBA 03/2024 - 01/2019
2	purineIBA 01/2023 - 11/2022
2	oxidized low density lipoproteinIBA 12/2022 - 12/2018
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2022 - 01/2014
2	Fibronectins (Fibronectin)IBA 01/2022 - 01/2019
2	Interleukin-1beta (Interleukin 1 beta)IBA 01/2021 - 09/2019
2	Semaxinib (SU5416)IBA 01/2021 - 01/2019
2	AcidsIBA 12/2020 - 11/2017
2	JNK Mitogen-Activated Protein KinasesIBA 09/2019 - 12/2018
2	Methionine (L-Methionine)FDA Link 09/2019 - 11/2016
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2019 - 12/2018
2	vadimezanIBA 12/2018 - 01/2017
2	Interferon Type IIBA 12/2018 - 01/2017
2	Insulin (Novolin)FDA Link 12/2018 - 05/2013
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 12/2018 - 01/2017
2	ArginaseIBA 01/2018 - 11/2017
2	Caffeine (No Doz)FDA LinkGeneric 01/2017 - 01/2017
2	AMP-Activated Protein KinasesIBA 03/2016 - 12/2012
2	ChemokinesIBA 01/2004 - 09/2002
1	S-Adenosylmethionine (Ademetionine)IBA 05/2024
1	histone H3 trimethyl Lys4IBA 05/2024
1	PDZ-binding kinaseIBA 04/2024
1	NucleotidesIBA 04/2024
1	VLDL LipoproteinsIBA 03/2024

Therapy/Procedure

4	Therapeutics 03/2024 - 07/2009
2	Lasers (Laser) 03/2024 - 11/2022
2	Drug Therapy (Chemotherapy) 01/2023 - 01/2022
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 11/2023